AngioDynamics, Inc. (ANGO) EPS Estimated At $0.20

March 14, 2018 - By Marguerite Chambers

 AngioDynamics, Inc. (ANGO) EPS Estimated At $0.20
Investors sentiment decreased to 1.17 in 2017 Q3. Its down 1.32, from 2.49 in 2017Q2. It dropped, as 13 investors sold AngioDynamics, Inc. shares while 52 reduced holdings. 24 funds opened positions while 52 raised stakes. 33.36 million shares or 0.00% more from 33.36 million shares in 2017Q2 were reported.
New York State Common Retirement Fund invested in 43,720 shares. Rhumbline Advisers reported 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Lapides Asset Mgmt Lc reported 1.66% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Bessemer Grp Inc has 63,200 shares. 65,000 were reported by State Of New Jersey Common Pension Fund D. Gotham Asset Management holds 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO) or 49,193 shares. First Quadrant Ltd Partnership Ca reported 0.02% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Teachers Retirement System Of The State Of Kentucky holds 0% or 11,000 shares in its portfolio. The California-based Assetmark has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Meeder Asset Mngmt reported 426 shares. Alliancebernstein L P accumulated 159,540 shares or 0% of the stock. Highbridge Management Ltd Liability Corp reported 25,304 shares or 0.01% of all its holdings. Loomis Sayles And Lp holds 1,796 shares. Manufacturers Life The holds 28,715 shares. State Street Corp stated it has 913,305 shares or 0% of all its holdings.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.20 EPS on March, 29 before the open.They anticipate $0.01 EPS change or 5.26 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.35M giving it 21.24 P/E if the $0.20 EPS is correct. After having $0.16 EPS previously, AngioDynamics, Inc.’s analysts see 25.00 % EPS growth. The stock decreased 1.22% or $0.21 during the last trading session, reaching $16.99. About 164,660 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since March 15, 2017 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 8 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. AngioDynamics had 20 analyst reports since July 24, 2015 according to SRatingsIntel. Raymond James downgraded the stock to “Mkt Perform” rating in Tuesday, November 10 report. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Buy” rating by Cantor Fitzgerald on Friday, November 4. As per Sunday, October 8, the company rating was maintained by Canaccord Genuity. The firm has “Neutral” rating by Piper Jaffray given on Friday, April 8. As per Friday, January 8, the company rating was maintained by Canaccord Genuity. The rating was downgraded by Canaccord Genuity to “Hold” on Tuesday, April 5. The company was maintained on Monday, July 10 by Canaccord Genuity. The firm has “Hold” rating by Craig Hallum given on Friday, January 5. The firm has “Equal-Weight” rating given on Wednesday, July 19 by Barclays Capital. Canaccord Genuity maintained AngioDynamics, Inc. (NASDAQ:ANGO) rating on Sunday, August 6. Canaccord Genuity has “Hold” rating and $1700 target.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $624.30 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It currently has negative earnings. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More notable recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: which released: “AngioDynamics’ (ANGO) CEO Jim Clemmer on Q2 2018 Results – Earnings Call …” on January 04, 2018, also with their article: “AngioDynamics (ANGO) Banks on Buyouts, Debt Level High” published on January 24, 2018, published: “AngioDynamics to Present at the 2017 Morgan Stanley Global Healthcare Conference” on August 29, 2017. More interesting news about AngioDynamics, Inc. (NASDAQ:ANGO) were released by: and their article: “AngioDynamics: Stay Away” published on January 23, 2018 as well as‘s news article titled: “AngioDynamics to Report Fiscal 2018 Third Quarter Financial Results on March …” with publication date: February 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: